Cognito Therapeutics Series B Extension

Cognito Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for Alzheimer's disease. Their lead product candidate, Spectris™, is a non-invasive, wearable neurostimulation device designed to treat cognitive decline associated with Alzheimer's. The company aims to address the underlying pathology of the disease by modulating brain activity.